Immutep Limited American Depositary Shares (IMMP) is a publicly traded Healthcare sector company. As of May 21, 2026, IMMP trades at $0.47 with a market cap of $72.80M and a P/E ratio of 0.00. IMMP moved -6.44% today. Year to date, IMMP is -85.04%; over the trailing twelve months it is -75.23%. Its 52-week range spans $0.29 to $3.53. Analyst consensus is neutral with an average price target of $0.00. Rallies surfaces IMMP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Immutep Gets Nasdaq Warning, Discontinues Phase III Lung Cancer Trial, Holds A$110.6M: Immutep received a Nasdaq notice for failing to maintain a US$1.00 ADS bid price over 30 consecutive business days, gaining until October 26 to restore compliance. In Q3 FY26, it discontinued the Phase III TACTI-004 lung cancer trial for futility and held A$110.6 million cash, funding operations into H1 CY2028.
| Metric | Value |
|---|---|
| Price | $0.47 |
| Market Cap | $72.80M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.53 |
| 52-Week Low | $0.29 |
| Volume | 9.83K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover IMMP: 0 strong buy, 0 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $0.00.